Eurofins tasked with streamlining disease testing by US kidney transplant group

By Gareth Macdonald contact

- Last updated on GMT

Viracor-IBT HQ in Missouri, US
Viracor-IBT HQ in Missouri, US

Related tags: Infectious disease, Infection

Eurofins has been contracted to streamline donor serology testing by the US National Kidney Registry (NKR).

The screening will be carried out by Eurofins’ subsidiary Viracor-IBT, which the contractor acquired in 2014 to expand its range of biomarker analysis capabilities and further engage with the biopharmaceutical and hospital sectors.

Under the agreement, Viracor-IBT will perform infectious disease screening at 75 NKR member centres. NKR said Viracor-IBT will help reduce kidney exchange or "swap" failures and increase the number of patients transplanted.

NKR founder Garet Hill said: “Infectious disease screening is a critical part of the paired exchange process. These tests need to be fast and accurate; otherwise swaps can be delayed, or worse, cancelled.

Through our partnership with Viracor-IBT we further streamline the pre-op serology testing process, reducing the turnaround for these tests to under two days from as much as 10 days, while providing secure electronic transmission of the results​."

This was echoed by Julie Kliegl, president of Viracor-IBT who added "as a laboratory committed to providing test results faster when it matters most, Viracor-IBT is thrilled to partner with the NKR on this critical program that accelerates donor-recipient matching and increases living donor transplantation."

From a business perspective, the agreement further underlines Eurofins growing focus on the human diagnostics sector.

Since buying Viracor-IBT, Eurofins has made a number of other purchases in the analysis space – Emory Genetics Laboratory, Biomnis and Diatherix Laboratories.​ The contract services firm has also invested €150m investment in lab group BioAccess.

Related news

Show more

Related products

show more

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q² Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Related suppliers

Follow us


View more